| Followers | 24 |
| Posts | 2534 |
| Boards Moderated | 0 |
| Alias Born | 12/17/2014 |
Wednesday, June 21, 2023 11:23:58 AM
$BDPT Thank you for posting this…here is the email script I received in its entirety…
“ Thank you for your recent inquiry to BioAdaptives. We appreciate your interest and your input. Whether a shareholder, potential investor, or an interested outside party we welcome all requests for information concerning our company.
Due to our sizable and diverse shareholder base, and the legal requirement to keep everyone as equally informed as possible, we utilize a variety of methods designed to share the latest most current Company information/data. First and foremost, we rely upon the forma reporting necessary to stay current with SEC requirements. Our 10-K and 10-Q submittals are comprehensive and timely, and, in addition, includes 8-K reports filed to announce material events. Other SEC submittals are filed as situations demand. Also, we utilize periodic press releases to report key events as posted on a variety of media outlets. Finally, our primary website, www.shopbioadaptives.com, as well as product specific sites, is dept current with news, products, and key activities/reports.
In these ways we attempt to provide a vehicle providing an opportunity to keep everyone interested in our company family fairly informed. As such, everyone has an equal access to all relevant information and data on a timely basis. As events and status change, we are committed to keeping the lines of communication current and helpful.
I hope this helps in understanding our standard process. Thanks again for your inquiry.
Bob Ellis, President & Director
BioAdaptives, Inc.
Las Vegas, Nevada USA
rwe@bioadaptives.com “
Feel free to reach out to him at his personal email address if anyone so chooses.
“ Thank you for your recent inquiry to BioAdaptives. We appreciate your interest and your input. Whether a shareholder, potential investor, or an interested outside party we welcome all requests for information concerning our company.
Due to our sizable and diverse shareholder base, and the legal requirement to keep everyone as equally informed as possible, we utilize a variety of methods designed to share the latest most current Company information/data. First and foremost, we rely upon the forma reporting necessary to stay current with SEC requirements. Our 10-K and 10-Q submittals are comprehensive and timely, and, in addition, includes 8-K reports filed to announce material events. Other SEC submittals are filed as situations demand. Also, we utilize periodic press releases to report key events as posted on a variety of media outlets. Finally, our primary website, www.shopbioadaptives.com, as well as product specific sites, is dept current with news, products, and key activities/reports.
In these ways we attempt to provide a vehicle providing an opportunity to keep everyone interested in our company family fairly informed. As such, everyone has an equal access to all relevant information and data on a timely basis. As events and status change, we are committed to keeping the lines of communication current and helpful.
I hope this helps in understanding our standard process. Thanks again for your inquiry.
Bob Ellis, President & Director
BioAdaptives, Inc.
Las Vegas, Nevada USA
rwe@bioadaptives.com “
Feel free to reach out to him at his personal email address if anyone so chooses.
Recent BDPT News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/15/2026 08:16:04 PM
- BioAdaptives introduces MyndSystem™, an integrated Neuro-Performance & Repair system for day and night • GlobeNewswire Inc. • 04/28/2026 02:00:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 04/14/2026 08:05:22 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 02:45:46 AM
- BioAdaptives® Announces Commercial Launch of MyndMed™ Following Successful Pilot Testing • GlobeNewswire Inc. • 10/07/2025 03:48:03 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 07:16:01 PM
